BioPharma Dive January 29, 2025
A short statement from CMS said the agency will consider ways to make Medicare price negotiations, begun under Biden, more transparent.
The Trump administration plans to proceed with negotiating Medicare prices for the next 15 drugs selected under the Inflation Reduction Act, but will seek input to “improve” the program, the Centers for Medicare and Medicaid Services said Wednesday.
The announcement comes amid some uncertainty about the new administration’s drug pricing priorities. On Inauguration Day, President Donald Trump issued an executive order rescinding a Biden administration initiative that had directed the health secretary to explore ways of lowering pharmaceutical costs within Medicare. While specific elements of that initiative appear to be continuing, the order created confusion about the White House’s...
Today's Sponsors
Today's Sponsor